OpenNashEarnings

Health Care · NYSE: MCK

McKesson earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends March · next results expected around 3 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q2 FY2027

McKesson deepened its push into specialty and oncology care, extending its CVS Health distribution deal through June 2032 and agreeing to a roughly 49% stake in Option Care Health.

McKesson extended its pharmaceutical distribution partnership with CVS Health through June 2032. Growth came from specialty products sold to health systems and strategic accounts, and from provider solutions and specialty distribution in Oncology & Multispecialty. Prescription Technology Solutions grew on third-party logistics and access solutions, though hub dispensing contributed less. In Medical-Surgical Solutions, a weaker product mix in ambulatory care held back profit. PRISM Vision Group added Spectrum Vision Partners, bringing its network to more than 350 providers.

Read the Q2 FY2027 summary →Q2 FY2027 slides (PDF) ↗Official transcript (PDF) ↗

Quarters

KPI history

Revenue$111.0B+7.6% y/yQ2 FY27
Q3 FY25: $95.3BQ3 25$95.3BQ4 FY25: $90.8B (worked out from the annual figure)Q4 25$90.8BQ1 FY26: $97.8BQ1 26$97.8BQ2 FY26: $103.2BQ2 26$103.2BQ3 FY26: $106.2BQ3 26$106.2BQ4 FY26: $96.3B (worked out from the annual figure)Q4 26$96.3BQ1 FY27: $105.4BQ1 27$105.4BQ2 FY27: $111.0BQ2 27$111.0B

Fourth quarter worked out from the annual figure.

Data
Q3 FY25$95.3B
Q4 FY25$90.8B *
Q1 FY26$97.8B
Q2 FY26$103.2B
Q3 FY26$106.2B
Q4 FY26$96.3B *
Q1 FY27$105.4B
Q2 FY27$111.0B
Diluted EPS (GAAP)$10.44+17.0% y/yQ2 FY27
Q3 FY25: $6.95Q3 25$6.95Q1 FY26: $6.25Q1 26$6.25Q2 FY26: $8.92Q2 26$8.92Q3 FY26: $9.59Q3 26$9.59Q1 FY27: $5.15Q1 27$5.15Q2 FY27: $10.44Q2 27$10.44
Data
Q3 FY25$6.95
Q1 FY26$6.25
Q2 FY26$8.92
Q3 FY26$9.59
Q1 FY27$5.15
Q2 FY27$10.44

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin1.4%+0.0 pts y/yQ2 FY27
Q3 FY25: 1.3%Q3 251.3%Q4 FY25: 1.8%Q4 251.8%Q1 FY26: 1.1%Q1 261.1%Q2 FY26: 1.4%Q2 261.4%Q3 FY26: 1.5%Q3 261.5%Q4 FY26: 2.2%Q4 262.2%Q1 FY27: 1.3%Q1 271.3%Q2 FY27: 1.4%Q2 271.4%
Data
Q3 FY251.3%
Q4 FY251.8%
Q1 FY261.1%
Q2 FY261.4%
Q3 FY261.5%
Q4 FY262.2%
Q1 FY271.3%
Q2 FY271.4%
Free cash flow$3.0B+29.9% y/yQ2 FY27
Q3 FY25: -$2.5BQ3 25-$2.5BQ4 FY25: $7.6BQ4 25$7.6BQ1 FY26: -$1.0BQ1 26-$1.0BQ2 FY26: $2.3BQ2 26$2.3BQ3 FY26: $1.1BQ3 26$1.1BQ4 FY26: $3.3BQ4 26$3.3BQ1 FY27: -$332.0MQ1 27-$332.0MQ2 FY27: $3.0BQ2 27$3.0B
Data
Q3 FY25-$2.5B
Q4 FY25$7.6B
Q1 FY26-$1.0B
Q2 FY26$2.3B
Q3 FY26$1.1B
Q4 FY26$3.3B
Q1 FY27-$332.0M
Q2 FY27$3.0B

Operating cash flow minus capital expenditure, from cash flow statements.

Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue$95.3B$90.8Bd$97.8B$103.2B$106.2B$96.3Bd$105.4B$111.0B
Gross margin3.4%4.0%3.4%3.4%3.5%4.2%3.5%3.6%
Operating income$1.2B$1.6Bd$1.0B$1.4B$1.6B$2.1Bd$1.3B$1.6B
Operating margin1.3%1.8%1.1%1.4%1.5%2.2%1.3%1.4%
Net income$879.0M$1.3Bd$784.0M$1.1B$1.2B$1.7Bd$614.0M$1.2B
Diluted EPS$6.95—$6.25$8.92$9.59—$5.15$10.44
Operating cash flow-$2.4Bd$7.7Bd-$918.0M$2.4Bd$1.2Bd$3.4Bd-$220.0M$3.1Bd
Capital expenditure$126.0Md$169.0Md$111.0M$106.0Md$108.0Md$111.0Md$112.0M$65.0Md
Free cash flow-$2.5B$7.6B-$1.0B$2.3B$1.1B$3.3B-$332.0M$3.0B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings